Home/Pipeline/ARY-002

ARY-002

Solid Tumors (Bispecific)

PreclinicalActive

Key Facts

Indication

Solid Tumors (Bispecific)

Phase

Preclinical

Status

Active

Company

AryoGen Pharmed

About AryoGen Pharmed

Israeli biotech leveraging AI‑enhanced antibody engineering to create novel oncology and immunology therapeutics.

View full company profile

Therapeutic Areas

Oncology Immunology